Capstone Therapeutics Corp. Announces Digital Corporate Communication Channels

TEMPE, Ariz., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (the "Company" or "Capstone Therapeutics"), a clinical stage biotechnology company developing a family of new peptide drugs, announced today its suite of online corporate communication channels to maintain on-going direct communication with stakeholders. The Company has launched official portals on social media channels including Facebook, Twitter, Google+ and The Chairman's Blog.

The Chairman's Blog is an online communication portal where Capstone Therapeutics' executives can address topics related to cardiovascular patients with high cholesterol, lipid and triglyceride levels as well as specific points of discussion as they relate to key events at Capstone Therapeutics. Executive Chairman, Jock Holliman, penned the Company's inaugural blog, "A New Class of Cardiovascular Drug," which can be found here:

"We are excited to announce the launch of our new digital communication channels," stated Mr. Holliman. "As the Company continues to make progress on the Homozygous Familial Hypercholesterolemia indication, and pursues potential indications in acute coronary syndrome and Type 2 diabetes, these new channels will allow us to communicate Company news with shareholders more effectively."

Links to the new communication tools are:




The Chairman's Blog Profile:

About Capstone Therapeutics Corp.

Capstone Therapeutics is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with cardiovascular disease. The Company is primarily focused on development and commercialization of Apo E Mimetic Peptide Molecule AEM-28 and its analogs (through the LipimetiX Development, LLC, joint venture).

For more information, please visit the Company's website:


Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include the factors discussed in our Form 10-K for the fiscal year ended December 31, 2013, and other documents we file with the U.S. Securities and Exchange Commission.

CONTACT: FOR FURTHER INFORMATION: Investor Relations (602) 286-5250

Source:Capstone Therapeutics